返回
New Developments in Imaging Cell-Based Therapy
DOI:10.2967/jnumed.118.213348.png)
摘要
En 中文
Cancer immunotherapy is now established as a central therapeutic pillar in hematologic oncology. Cell-based therapies, with or without genetic modification ex vivo, have reached the clinic as the standard of care in limited indications and remain the subject of intense preclinical and translational development. Expanding on this, related therapeutic approaches are in development for solid-tumor and nonmalignant indications, broadening the scope of this technology. It has long been recognized that in vivo tracking of infused cellular therapies would provide unique opportunities to optimize their efficacy and aid in the assessment and management of toxicity. Recently, we have witnessed the introduction of novel tracers for passive labeling of cell products and advances in the introduction and use of reporter genes to enable longitudinal imaging. This review highlights the key developments over the last 5 y.
Keyword:
molecular imaging
oncology
radioimmunoimaging
cell therapy
radiotracers
AI总结
对已上传原文的论文进行重点信息的提取,主要内容包括:简要概述、研究摘要、背景介绍、关键亮点、图文解析、展望与总结。
期刊
IF:
9.1
论文数:
6.2K
被引数:
3.0W
机构
引用论文
Antibody with Infinite Affinity for In Vivo Tracking of Genetically Engineered Lymphocytes具有无限亲和力的抗体,用于体内追踪基因工程淋巴细胞
Micromolar affinity CAR T cells to ICAM-1 achieves rapid tumor elimination while avoiding systemic toxicity
SCIENTIFIC REPORTS
IF3.9
A renal-targeted triptolide aminoglycoside (TPAG) conjugate for lowering systemic toxicities of triptolide
Fitoterapia
IF0

